Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA known ✓ | P35790 | 2/20 | 0.55 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.44 |
| ▸ | CHRM5 known ✓ | P08912 | 2/20 | 0.44 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.44 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.44 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.44 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | RAD52 | P43351 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.50 |
| ▸ | CHRNA10 | Q9GZZ6 | 2/20 | 0.50 |
| ▸ | CHRNA9 | Q9UGM1 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13334099 | 0.98 | HTT (0.69) | HTTKMT2AMEN1MAPTRAD52 | |
| SCHEMBL4405443 | 0.91 | HTT (0.61) | HTTKMT2AMEN1MAPTRAD52 | |
| SCHEMBL13361695 | 0.89 | HTT (0.60) | HTTKMT2AMEN1MAPTRAD52 | |
| Bromide SCHEMBL9362559 | 0.85 | HTT (0.91) | HTTKMT2AMEN1MAPTRAD52 | |
| SCHEMBL16405358 | 0.84 | CHRM2 (0.62) | HTTKMT2AMEN1MAPTRAD52 | |
| Bromide SCHEMBL8659288 | 0.83 | KMT2A (0.64) | HTTKMT2AMEN1MAPTRAD52 | |
| Bromide SCHEMBL1502789 | 0.83 | HTT (0.96) | HTTKMT2AMEN1MAPTRAD52 | |
| Bromide SCHEMBL9362504 | 0.83 | HTT (0.96) | HTTKMT2AMEN1MAPTRAD52 | |
| Bromide SCHEMBL1502820 | 0.83 | HTT (0.96) | HTTKMT2AMEN1MAPTRAD52 | |
| Miripirium SCHEMBL10323639 | 0.83 | HTT (0.96) | HTTKMT2AMEN1MAPTRAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371266-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIV KENTUCKY RES FOUND (US) | 2014-12-18 | — | — | US | claimed |
| US-8846937-B2 | Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-09-30 | — | — | US | claimed |
| US-20100113511-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-05-06 | — | — | US | claimed |
| WO-2007149392-A1 | MONO QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS | UNIVERSITY OF KENTUCKY (US) | 2007-12-27 | — | — | WO | claimed |
| US-9550753-B2 | Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2017-01-24 | — | — | US | disclosed |
| US-20140371266-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIV KENTUCKY RES FOUND (US) | 2014-12-18 | — | — | US | disclosed |
| US-8846937-B2 | Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-09-30 | — | — | US | disclosed |
| US-20100113511-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2007149392-A1 | MONO QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS | UNIVERSITY OF KENTUCKY (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113511-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | CHRNA2, CHRNA4, CHRNA5 | CHKA 272/4885CHRM2 20/4885CHRM5 18/4885 |
| US-20140371266-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | CHRNA2, CHRNA4, CHRNA5 | CHKA 271/4885CHRM2 20/4885CHRM5 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.